| |
Tuesday, October 1, 2024 | 11am ET / 8am PT The clinical trial landscape continues to evolve at a rapid pace. In this webinar, learn how new biomarker detection technologies drive key breakthroughs. With early detection, biomarker testing research can advance disease understanding and management in many care areas. Register now to join us. 
|
|
Today’s Big NewsSep 24, 2024 |
| By Nick Paul Taylor Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus and outlining plans to start a second pivotal trial. |
|
|
|
By Angus Liu The FDA is having second thoughts about the broad labels it has granted PD-1 inhibitors in newly diagnosed stomach cancer, questioning whether restrictions should be placed on products from Bristol Myers Squibb, Merck & Co. and BeiGene. |
By Angus Liu After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%, or nearly 100 employees. |
By Gabrielle Masson While the biotech has yet to unveil a more detailed data set, the injection, dubbed MET-097, was tied to “significant and durable” weight loss. |
|
Tuesday, October 8, 2024 |10am ET / 7am PT In this webinar, you'll learn how companies can navigate the challenges of global expansion after their first regulatory approval. Discover how to make data-driven market entry decisions, launch efficiently, stay adaptable, and leverage commercial partners through case studies and real-life examples. Sign up to join us! 
|
|
By Conor Hale ICU Medical’s Smiths Medical division first began notifying healthcare providers of the separate issues in late May and early June. |
By Gabrielle Masson Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein therapeutics across multiple indications. |
By Nick Paul Taylor Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of biosimilar competition, polling doctors about forces shaping the market and their preferred off-patent options. |
By Zoey Becker Ahead of a hearing on Ozempic and Wegovy prices, prepared remarks from Novo CEO Lars Fruergaard Jørgensen shine a light on the larger U.S. healthcare system. |
By Gabrielle Masson After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi. |
By Conor Hale Neurable is putting forward a pair of headphones equipped with sensors to measure mental activity—in what it describes as the first brain-computer interface of its kind aimed at the general consumer. |
By Fraiser Kansteiner PCI has “heavily invested” in new drug delivery tech at its Philadelphia headquarters, laid plans for a 545,000-square-foot expansion in Rockford, Illinois, acquired a new packaging and device assembly plant near Dublin, Ireland, and broken ground on another at its CityNorth Dublin campus. Altogether, PCI’s manufacturing projects represent an investment of more than $365 million. |
By Andrea Park Currax Pharmaceuticals is working to raise awareness of the concept of food noise as a psychological barrier to weight loss. |
By Kevin Dunleavy Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar. |
By Conor Hale Supplied by Novo Holdings, the financing comes as an extension to its series F round, which had previously announced a collection of more than $31 million in November 2023. |
By Andrea Park While AstraZeneca’s previous efforts to showcase the power of science have taken a broader approach, highlighting clinical discoveries, new technologies and sustainability work, the drugmaker’s newest corporate campaign gets into the nitty-gritty of science’s impact on individual patients’ everyday lives. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East. |
|
|---|
|
|
|
The effect of small strands of siRNAs on gene expression has had a
tremendous impact on basic and applied pharmaceutical research.
Download the QPS white paper to learn about siRNA identification,
profiling, and quantitation from the technical experts at QPS. +(2).png)
|
|
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
